UF Health Cancer Center Support Grant - Training Navigator Supplement
佛罗里达大学健康癌症中心支持补助金 - 培训导航补充
基本信息
- 批准号:10892335
- 负责人:
- 金额:$ 19.59万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-06-01 至 2024-05-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdministrative SupplementAwardAwarenessBehavioral SciencesCaliforniaCancer CenterCancer Center Support GrantCaringCatchment AreaDevelopmentDiverse WorkforceEducationEducational workshopEvaluationExhibitsFloridaFundingGoalsGrantHealthHybridsIndividualLearningMalignant NeoplasmsMeasuresMentorshipMissionMonitorOnline SystemsOutcomePathway interactionsPostdoctoral FellowPreparationProductivityPublic HealthPublicationsResearch PersonnelResearch TrainingSeriesSystemTrainingUnderrepresented MinorityUnited States National Institutes of HealthUniversitiesWorkWritinganticancer researchcancer health disparitycareer developmenteducation researchhealth equityimprovedinnovationminority disparityminority traineeminority undergraduatenext generationpre-doctoralprogramsrecruitsuccesssymposium
项目摘要
The University of Florida Health Cancer Center (UFHCC) recognizes that achieving health equity requires
inclusive education, training, recruitment, retention, and promotion of the next generation of cancer researchers.
Therefore, this Administrative Supplement application aims to recruit and develop a cadre of independent
researchers prepared to address cancer disparities in our catchment area. This supplement will enhance the
synergistic impact of CaRTEC, DEI, and the Florida-California Cancer Research, Education and Engagement
(CaRE2) Health Equity Center by focusing on developing underrepresented minority (URM) pre-doc, post-doc,
and early-stage investigators (ESIs). To expand upon the success of CaRTEC and CaRE2, and achieve their
long-term goal of improving training outcomes of URM trainees and ESIs, a Training Navigator Team (TNT) will
be implemented to 1) bridge activities between CaRTEC, DEI, and CaRE2 programs at the UFHCC; 2) facilitate
the entry of URM into the cancer research training pipeline; and 3) prepare trainees and ESIs to pursue career
development opportunities provided by the Center to Reduce Cancer Health Disparities CURE program and
beyond. This collaborative effort seeks to build upon the successes of each program through the following
objectives: 1) implement a TNT to attract, recruit, and support competitive underrepresented trainees and ESIs,
and facilitate their entry into NIH-supported pathway programs at the UFHCC and the attainment of NCI funding;
2) provide professional preparation and networking opportunities for scholars through grant writing and technical
assistance workshops (TAWs); and 3) monitor, track, and evaluate the progress and productivity of trainees and
ESIs. In particular, the TNT will help recruit URM trainees regionally, from partnering MSIs, as well as national
conferences to exhibit the work of minoritized undergraduate researchers. In addition, a series of 5 training
assistance workshops (TAWs) will be developed to prepare trainees and ESIs to pursue CURE funding. All
TAWs will be recorded and content will be used to develop an innovative hybrid and asynchronous course that
will be offered through the University's web-based learning management system. Metrics will be tracked on new
cancer-relevant awards and publications, proposals and supplements submitted and the corresponding funding
rate, and mentorship activities for trainees. Evaluations using the CPACHE U54 Research Education Shared
Measures Toolkit will also determine the impact of proposed activities on funding and career development. This
application is significant because it will increase the number of URM trainees at the UFHCC, increase the
awareness around URM- and cancer disparities-relevant funding, and improve the capacity for URM UFHCC
trainees to pursue external funding. This program will be impactful because it will help recruit >15 post-bacs,
pre-docs, post-docs, and fellows and will engage >40 pre-docs, post-docs, fellows, and ESIs in TAWs who will
submit a total of 10 CURE-supported applications in 2023-2024.
佛罗里达大学健康癌症中心(UFHCC)认识到,实现健康公平需要
全纳教育、培训、招聘、留用和提拔下一代癌症研究人员。
因此,本行政副刊申请旨在招聘和发展一支独立的干部队伍
研究人员准备解决我们集水区癌症差异的问题。这份补充资料将加强
CARTEC、DEI和佛罗里达-加州癌症研究、教育和参与项目的协同影响
(Care2)健康公平中心,重点发展代表不足的少数群体(URM)博士前、博士后、
和早期调查人员(Esis)。在CARTEC和CARE2的成功基础上进行扩展,并实现其
为了改善URM学员和ESIS的培训结果,一个培训导航员团队(TNT)将
实施以1)在UFCC的CARTEC、DEI和Care2计划之间架起桥梁;2)促进
URM进入癌症研究培训渠道;3)为受训人员和EIS做好职业发展的准备
该中心提供的发展机会,以减少癌症健康差距治疗计划和
更远一点。这种合作努力寻求通过以下方式在每个项目的成功基础上再接再厉
目标:1)实施TNT,以吸引、招募和支持竞争激烈、代表性不足的学员和EIS,
并为他们进入加州大学旧金山分校的NIH支持的路径项目和获得NCI资金提供便利;
2)通过撰写赠款和技术支持,为学者提供专业准备和网络机会
援助讲习班(TAWS);以及3)监测、跟踪和评估受训人员的进展和生产力以及
艾西斯。特别是,TNT将帮助从与MSI合作的地区以及全国范围内招募URM实习生
展示小规模本科生研究人员工作的会议。此外,一系列5个培训
将举办援助讲习班(TAWS),为学员和ESIS寻求治疗资金做好准备。全
TAWS将被录制,内容将被用来开发一个创新的混合和异步课程,
将通过该大学的基于网络的学习管理系统提供。指标将在新的
已提交的与癌症有关的奖项和出版物、提案和补充资料以及相应的资金
评级,并为学员提供辅导活动。使用CPACHE U54研究教育共享的评估
MEASURES工具包还将确定拟议活动对供资和职业发展的影响。这
应用程序意义重大,因为它将增加UFCC的URM实习生数量,增加
对URM-和癌症差异-相关资金的认识,并提高URM UFCC的能力
受训人员寻求外部资金。这一计划将产生影响,因为它将帮助招聘15名毕业后的毕业生,
博士后、博士后和研究员,并将在陶斯聘用40名博士后、博士后、研究员和Esis
2023-2024年共提交10份治愈支持申请。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Histone mutations in cancer.
- DOI:10.1042/bst20210567
- 发表时间:2023-10-31
- 期刊:
- 影响因子:3.9
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jonathan D. Licht其他文献
Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiPl
肿瘤抑制因子 BRCA1 对细胞周期的抑制需要 CDK 抑制剂 p21WAF1/CiP1
- DOI:
10.1038/38291 - 发表时间:
1997-09-11 - 期刊:
- 影响因子:48.500
- 作者:
Kumaravel Somasundaram;Hongbing Zhang;Yi-Xin Zeng;Yariv Houvras;Yi Peng;Hongxiang Zhang;Gen Sheng Wu;Jonathan D. Licht;Barbara L. Weber;Wafik S. El-Deiry - 通讯作者:
Wafik S. El-Deiry
HLA-DR, CD33<sup>+</sup>, CD56<sup>+</sup>, CD16<sup>-</sup> Myeloid/Natural Killer Cell Acute Leukemia: A Previously Unrecognized Form of Acute Leukemia Potentially Misdiagnosed as French-American-British Acute Myeloid Leukemia-M3
- DOI:
10.1182/blood.v84.1.244.244 - 发表时间:
1994-07-01 - 期刊:
- 影响因子:
- 作者:
Amy A. Scott;David R. Head;Kenneth J. Kopecky;Frederick R. Appelbaum;Karl S. Theil;Michael R. Grever;l-Ming Chen;Michael H. Whittaker;Barbara B. Griffith;Jonathan D. Licht;Samuel Waxman;Margaret M. Whalen;Arthur D. Bankhurst;Lynn C. Richter;Thomas M. Grogan;Cheryl L. Willman - 通讯作者:
Cheryl L. Willman
Compound Loss of <em>Dnmt3a</em> and <em>Kmt2c</em> in Myeloid Malignancies
- DOI:
10.1182/blood-2023-189411 - 发表时间:
2023-11-02 - 期刊:
- 影响因子:
- 作者:
Prabhjot Kaur;Cassandra Berntsen;James Leonard;Daniil Shabashvili;Qingchen Yuan;Bowen Yan;Richard Lynn Bennett;Alberto Riva;Jonathan D. Licht;Olga A. Guryanova - 通讯作者:
Olga A. Guryanova
Synergistic Effect of Trifluridine and PARPi Combination in Targeting <em>TP53</em>-Mutated AML
- DOI:
10.1182/blood-2024-201781 - 发表时间:
2024-11-05 - 期刊:
- 影响因子:
- 作者:
Phani Krishna Parcha;Vivek M. Shastri;Jonathan D. Licht;Jatinder K. Lamba - 通讯作者:
Jatinder K. Lamba
Sprouty1 Controls Genitourinary Development via its N-Terminal Tyrosine.
Sprouty1 通过其 N 端酪氨酸控制泌尿生殖系统的发育。
- DOI:
10.1681/asn.2018111085 - 发表时间:
2019 - 期刊:
- 影响因子:0
- 作者:
M. Vaquero;S. Cuesta;C. Anerillas;Gisela Altés;J. Ribera;M. Albert Basson;Jonathan D. Licht;J. Egea;M. Encinas - 通讯作者:
M. Encinas
Jonathan D. Licht的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jonathan D. Licht', 18)}}的其他基金
Exploring microRNA degradation in T-cell acute lymphoblastic leukemia
探索 T 细胞急性淋巴细胞白血病中的 microRNA 降解
- 批准号:
10717486 - 财政年份:2023
- 资助金额:
$ 19.59万 - 项目类别:
University of Florida Health Cancer Center Support Grant
佛罗里达大学健康癌症中心支持补助金
- 批准号:
10625750 - 财政年份:2023
- 资助金额:
$ 19.59万 - 项目类别:
Defining and targeting epigenetic plasticity-driven drug resistance and immune escape in melanoma
定义和针对黑色素瘤中表观遗传可塑性驱动的耐药性和免疫逃逸
- 批准号:
10666665 - 财政年份:2022
- 资助金额:
$ 19.59万 - 项目类别:
KDM6A mutation as an epigenetic driver of multiple myeloma
KDM6A 突变作为多发性骨髓瘤的表观遗传驱动因素
- 批准号:
10229675 - 财政年份:2020
- 资助金额:
$ 19.59万 - 项目类别:
2019 Cancer Genetics and Epigenetics GRC/GRS
2019年癌症遗传学和表观遗传学GRC/GRS
- 批准号:
9754282 - 财政年份:2019
- 资助金额:
$ 19.59万 - 项目类别:
The Role of MMSET in the Pathogenesis and Progression of Lymphoid Malignancy
MMSET 在淋巴恶性肿瘤发病机制和进展中的作用
- 批准号:
9330809 - 财政年份:2016
- 资助金额:
$ 19.59万 - 项目类别:
The Role of MMSET in the Pathogenesis and Progression of Lymphoid Malignancy
MMSET 在淋巴恶性肿瘤发病机制和进展中的作用
- 批准号:
9759647 - 财政年份:2016
- 资助金额:
$ 19.59万 - 项目类别:
Spatio-Temporal Organization of Chromatin and Information Transfer in Cancer
癌症中染色质的时空组织和信息传递
- 批准号:
8866966 - 财政年份:2015
- 资助金额:
$ 19.59万 - 项目类别:
相似海外基金
2023 NINDS Landis Mentorship Award - Administrative Supplement to NS121106 Control of Axon Initial Segment in Epilepsy
2023 年 NINDS 兰迪斯指导奖 - NS121106 癫痫轴突初始段控制的行政补充
- 批准号:
10896844 - 财政年份:2023
- 资助金额:
$ 19.59万 - 项目类别:
Administrative Supplement for Award 93818 (R01GM144578)
奖励行政补遗 93818 (R01GM144578)
- 批准号:
10798445 - 财政年份:2022
- 资助金额:
$ 19.59万 - 项目类别:
Administrative Supplement to existing K08 award - K08DK120934-01-04 Van Batavia J - Role of CRH-neurons BN/Uncovering Heterogeneity of BN
现有 K08 奖项的行政补充 - K08DK120934-01-04 Van Batavia J - CRH 神经元 BN 的作用/揭示 BN 的异质性
- 批准号:
10629808 - 财政年份:2022
- 资助金额:
$ 19.59万 - 项目类别:
Administrative Supplement for DePaul-Silva K22 award
德保罗-席尔瓦 K22 奖行政补充
- 批准号:
10675275 - 财政年份:2021
- 资助金额:
$ 19.59万 - 项目类别:
Administrative Supplement to Support Summer Undergraduate Research for the Parent MIRA Award R35 GM141891 “Mechanistic Pharmacodynamic Modeling for Drug Combinations"
支持家长 MIRA 奖 R35 GM141891 暑期本科生研究的行政补充 — 药物组合的机械药效学建模”
- 批准号:
10809119 - 财政年份:2021
- 资助金额:
$ 19.59万 - 项目类别:
Administrative Supplement to Support Collaborations to Improve AIML-Readiness of NIH-Supported Data for Parent Award SCH: Personalized Rescheduling of Adaptive Radiation Therapy for Head & Neck Cancer
支持合作的行政补充,以提高 NIH 支持的家长奖数据的 AIML 就绪性 SCH:头部自适应放射治疗的个性化重新安排
- 批准号:
10594327 - 财政年份:2021
- 资助金额:
$ 19.59万 - 项目类别:
Administrative Supplement (PA-20-272) to Expand Safe Insulin De-Prescribing (R01 Award) to include Patients with ADRD and Their Caregivers
行政补充文件 (PA-20-272) 将安全胰岛素取消处方(R01 奖)扩大到包括 ADRD 患者及其护理人员
- 批准号:
10492857 - 财政年份:2020
- 资助金额:
$ 19.59万 - 项目类别:
Administrative Supplement to Award "Circadian regulation of vascular aging"
“血管老化的昼夜节律调节”奖行政补充
- 批准号:
10283788 - 财政年份:2019
- 资助金额:
$ 19.59万 - 项目类别:
Administrative Supplement to 1U54EB020404 award Mobile Data to Knowledge: Combining Genomic and Mobile Data Around Physical Activity
1U54EB020404 奖移动数据到知识的行政补充:围绕身体活动结合基因组和移动数据
- 批准号:
9198625 - 财政年份:2014
- 资助金额:
$ 19.59万 - 项目类别:














{{item.name}}会员




